長聖國際生技股份有限公司 (Ever Supreme Bio Technology Co., Ltd) (6712) 2024Q4 法說會簡報

Company Overview

• Company Name: 長聖國際生技股份有限公司 (Ever Supreme Bio Technology Co., Ltd)
• Stock Code: 6712
• Founding Date: December 2016
• Listing Date: January 2021
• Capital: NT$ 806,726 thousand
• Company Representative/Chairman: 劉銖淇 (Chairman Liu Zhuqi)
• Number of Employees: 89, with approximately 70% holding medical and biological master's or doctoral degrees.
• Location: 長聖中科廠 (Ever Supreme in CTSP)

Financial Highlights

• Annual Revenue (NT$):
  • 2020: 70,597
  • 2021: 438,841
  • 2022: 627,512
  • 2023: 759,580
  • 2024 (projected): 939,471
• Pre-tax EPS (Earnings Per Share):
  • 2024 pre-tax EPS projected to be above NT$6.

Business Segments

• Core Technology Platforms:
  1. 幹細胞培養及增生技術 (Stem Cell Culture and Proliferation Technology)
  2. 特殊免疫細胞培養技術 (Special Immune Cell Culture Technology)
  3. 奈米粒子製藥技術 (Nanoparticle Pharmaceutical Technology)
  4. 外泌體培養技術 (Exosome Culture Technology)
• Business Model:
  • 新藥開發 (IND) (New Drug Development): Focused on innovative therapies based on core technology platforms.
  • 細胞委託製造服務 (CDMO) (Cell Contract Development and Manufacturing Organization): Provides manufacturing services for cell preparations.

Products & Technologies

• Products/Therapies:
  • CAR001 (CAR.BITE): Antigen-binding receptor T Cell.
  • UMSC (Umbilical Cord Mesenchymal Stem Cell) - UMSC01
  • INSP (Innovative Taxane)
  • Exosome
• Technology Platforms:
  • Immune Cell Technology Platform
  • Stem Cell Technology Platform
  • Nanoparticle Pharmaceutical Platform
  • Exosome Technology Platform

Clients & Markets

• Partnered with 19 medical institutions for approval.
• Enrolled over 800 patients.

ESG / Sustainability

No specific ESG or sustainability information provided.

Outlook & Strategy

• Future Vision (2024/11-2029): To become a leading cell pharmaceutical company in the Asia-Pacific region.
• Strategic Direction:
  • Focus on allogeneic cell therapy using healthy donor cells.
  • Expand global market with Taiwan as the R&D base.
• Future Profit Drivers (新藥授權 - New Drug Licensing):
  • CAR001
  • CAR-MSC
  • INSP
  • Exosome

Additional Data

• Monthly Revenue (NT$):
  • 2023:
    • Jan: 33,183
    • Feb: 39,044
    • Mar: 44,656
    • Apr: 48,613
    • May: 54,022
    • Jun: 57,304
    • Jul: 60,604
    • Aug: 78,804
    • Sep: 87,189
    • Oct: 87,514
    • Nov: 87,601
    • Dec: 81,055
  • 2024 (projected):
    • Jan: 53,502
    • Feb: 54,895
    • Mar: 55,081
    • Apr: 56,032
    • May: 60,120
    • Jun: 62,127
    • Jul: 70,210
    • Aug: 87,789
    • Sep: 90,026
    • Oct: 99,087
    • Nov: 123,484
    • Dec: 127,118
• Key Performance Highlights (2024 projections):
  • December 2024 revenue: NT$127 million, a 56.8% growth compared to the previous year.
  • Q4 2024 quarterly revenue: NT$349 million, a 36.4% increase year-on-year.
  • Full-year cumulative revenue: NT$939 million, a 23.6% growth compared to the previous year's NT$759 million.